O	0	1	A
O	2	13	multicenter
O	14	24	randomized
O	25	30	trial
O	31	33	of
O	34	37	the
O	38	45	effects
O	46	48	of
B-intervention	49	57	exercise
O	58	62	dose
O	63	66	and
O	67	71	type
O	72	74	on
B-condition	75	87	psychosocial
I-condition	88	96	distress
O	97	99	in
B-eligibility	100	106	breast
I-eligibility	107	113	cancer
I-eligibility	114	122	patients
I-eligibility	123	133	undergoing
I-eligibility	134	146	chemotherapy
O	146	147	.

O	148	156	Exercise
O	157	160	may
O	161	168	improve
O	169	181	psychosocial
O	182	190	distress
O	191	193	in
O	194	202	patients
O	203	207	with
O	208	214	cancer
O	214	215	;
O	216	223	however
O	223	224	,
O	225	228	few
O	229	236	studies
O	237	241	have
O	242	250	examined
O	251	254	the
O	255	262	effects
O	263	265	of
O	266	275	different
O	276	281	types
O	282	284	or
O	285	290	doses
O	291	293	of
O	294	302	exercise
O	302	303	,
O	304	306	or
O	307	314	whether
O	315	323	exercise
O	324	331	effects
O	332	335	are
O	336	343	related
O	344	346	to
O	347	355	baseline
O	356	366	depression
O	367	373	levels
O	373	374	.

O	375	377	In
O	378	379	a
O	380	391	multicenter
O	392	397	trial
O	398	400	in
B-location	401	407	Canada
O	407	408	,
O	409	411	we
O	412	422	randomized
B-total-participants	423	426	301
B-eligibility	427	435	patients
I-eligibility	436	440	with
I-eligibility	441	447	breast
I-eligibility	448	454	cancer
I-eligibility	455	465	initiating
I-eligibility	466	478	chemotherapy
O	479	481	to
O	482	488	thrice
O	489	495	weekly
O	495	496	,
O	497	507	supervised
O	508	516	exercise
O	517	527	consisting
O	528	530	of
O	531	537	either
O	538	539	a
O	540	548	standard
O	549	553	dose
O	554	556	of
O	557	559	25
O	560	562	to
O	563	565	30
O	566	573	minutes
O	574	576	of
O	577	584	aerobic
O	585	593	exercise
O	594	595	(
O	595	599	STAN
O	599	600	;
O	601	602	n
O	603	604	=
B-intervention-participants	605	607	96
O	607	608	)
O	608	609	,
O	610	611	a
O	612	618	higher
O	619	623	dose
O	624	626	of
O	627	629	50
O	630	632	to
O	633	635	60
O	636	643	minutes
O	644	646	of
O	647	654	aerobic
O	655	663	exercise
O	664	665	(
O	665	669	HIGH
O	669	670	;
O	671	672	n
O	673	674	=
B-intervention-participants	675	678	101
O	678	679	)
O	679	680	,
O	681	683	or
O	684	685	a
O	686	694	combined
O	695	699	dose
O	700	702	of
O	703	705	50
O	706	708	to
O	709	711	60
O	712	719	minutes
O	720	722	of
O	723	730	aerobic
O	731	734	and
O	735	745	resistance
O	746	754	exercise
O	755	756	(
O	756	760	COMB
O	760	761	;
O	762	763	n
O	764	765	=
B-intervention-participants	766	769	104
O	769	770	)
O	770	771	.

O	772	775	The
O	776	783	primary
O	784	792	endpoint
O	793	796	was
B-outcome-Measure	797	807	depression
O	808	816	assessed
O	817	819	by
O	820	823	the
O	824	830	Center
O	831	834	for
O	835	850	Epidemiological
O	851	858	Studies
O	858	859	-
O	859	869	Depression
O	870	875	scale
O	876	878	at
O	879	887	baseline
O	887	888	,
O	889	894	twice
O	895	901	during
O	902	914	chemotherapy
O	914	915	,
O	916	919	and
O	920	936	postchemotherapy
O	936	937	.

O	938	947	Secondary
O	948	957	endpoints
O	958	962	were
B-outcome-Measure	963	970	anxiety
O	970	971	,
B-outcome-Measure	972	981	perceived
I-outcome-Measure	982	988	stress
O	988	989	,
O	990	993	and
B-outcome-Measure	994	998	self
I-outcome-Measure	998	999	-
I-outcome-Measure	999	1005	esteem
O	1005	1006	.

O	1007	1015	Repeated
O	1016	1024	measures
O	1025	1030	ANOVA
O	1031	1040	indicated
O	1041	1045	that
O	1046	1053	neither
O	1054	1058	HIGH
O	1059	1060	[
O	1060	1064	mean
O	1065	1075	difference
O	1076	1077	=
O	1078	1079	-
O	1079	1080	0
O	1080	1081	.
O	1081	1082	9
O	1082	1083	;
O	1084	1086	95
O	1086	1087	%
O	1088	1098	confidence
O	1099	1107	interval
O	1108	1109	(
O	1109	1111	CI
O	1111	1112	)
O	1112	1113	,
O	1114	1115	+
O	1115	1116	0
O	1116	1117	.
O	1117	1118	0
O	1119	1121	to
O	1122	1123	-
O	1123	1124	1
O	1124	1125	.
O	1125	1126	8
O	1126	1127	;
O	1128	1129	P
O	1130	1131	=
O	1132	1133	0
O	1133	1134	.
O	1134	1137	061
O	1137	1138	]
O	1139	1142	nor
O	1143	1147	COMB
O	1148	1149	(
O	1149	1153	mean
O	1154	1164	difference
O	1165	1166	=
O	1167	1168	-
O	1168	1169	0
O	1169	1170	.
O	1170	1171	4
O	1171	1172	;
O	1173	1175	95
O	1175	1176	%
O	1177	1179	CI
O	1179	1180	,
O	1181	1182	+
O	1182	1183	0
O	1183	1184	.
O	1184	1185	5
O	1186	1188	to
O	1189	1190	-
O	1190	1191	1
O	1191	1192	.
O	1192	1193	3
O	1193	1194	;
O	1195	1196	P
O	1197	1198	=
O	1199	1200	0
O	1200	1201	.
O	1201	1203	36
O	1203	1204	)
O	1205	1208	was
O	1209	1217	superior
O	1218	1220	to
O	1221	1225	STAN
O	1226	1229	for
B-outcome	1230	1238	managing
I-outcome	1239	1249	depressive
I-outcome	1250	1258	symptoms
O	1258	1259	.

O	1260	1262	In
O	1263	1264	a
O	1265	1272	planned
O	1273	1281	subgroup
O	1282	1290	analysis
O	1290	1291	,
O	1292	1297	there
O	1298	1301	was
O	1302	1303	a
O	1304	1315	significant
O	1316	1327	interaction
O	1328	1332	with
O	1333	1341	baseline
B-outcome	1342	1352	depression
I-outcome	1353	1359	levels
O	1360	1361	(
O	1361	1362	P
O	1363	1374	interaction
O	1375	1376	=
O	1377	1378	0
O	1378	1379	.
O	1379	1382	027
O	1382	1383	)
O	1384	1394	indicating
O	1395	1399	that
O	1400	1404	COMB
O	1405	1408	and
O	1409	1413	HIGH
O	1414	1418	were
O	1419	1428	effective
O	1429	1432	for
O	1433	1441	managing
O	1442	1452	depressive
O	1453	1461	symptoms
O	1462	1464	in
O	1465	1473	patients
O	1474	1478	with
O	1479	1487	clinical
O	1488	1494	levels
O	1495	1497	of
O	1498	1508	depressive
O	1509	1517	symptoms
O	1518	1520	at
O	1521	1529	baseline
O	1529	1530	.

O	1531	1539	Compared
O	1540	1544	with
O	1545	1546	a
O	1547	1555	standard
O	1556	1562	volume
O	1563	1565	of
O	1566	1573	aerobic
O	1574	1582	exercise
O	1582	1583	,
O	1584	1590	higher
O	1591	1598	volumes
O	1599	1601	of
O	1602	1610	exercise
O	1611	1614	did
O	1615	1618	not
O	1619	1623	help
O	1624	1630	manage
B-outcome	1631	1641	depressive
I-outcome	1642	1650	symptoms
O	1651	1653	in
O	1654	1664	unselected
O	1665	1673	patients
O	1674	1678	with
O	1679	1685	breast
O	1686	1692	cancer
O	1693	1702	receiving
O	1703	1715	chemotherapy
O	1715	1716	,
O	1717	1720	but
O	1721	1725	they
O	1726	1730	were
O	1731	1740	effective
O	1741	1743	in
O	1744	1752	patients
O	1753	1757	with
O	1758	1766	clinical
O	1767	1773	levels
O	1774	1776	of
O	1777	1787	depressive
O	1788	1796	symptoms
O	1797	1799	at
O	1800	1808	baseline
O	1808	1809	.

O	1810	1811	A
O	1812	1817	phase
O	1818	1821	III
O	1822	1830	exercise
O	1831	1836	trial
O	1837	1846	targeting
O	1847	1856	depressed
O	1857	1865	patients
O	1866	1870	with
O	1871	1877	breast
O	1878	1884	cancer
O	1885	1887	is
O	1888	1897	warranted
O	1897	1898	.
